All In MedTech

Device Trial Radar · NCT06616519

A Study to Evaluate the Safety and Efficacy of MSENC1 Soft Hydrophilic Contact Lenses and Oxypure Color Soft Hydrophilic Contact Lenses

Multi-center, Open, Parallel, and Randomly Controlled Comparison Between MSENC1 Soft Hydrophilic Contact Lenses and Oxypure Color Soft Hydrophilic Contact Lenses in Their Safety and Efficacy

Last checked: Nov 20, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

192

Actual

Start

May 18, 2021

Primary completion

May 1, 2022

Study completion Aug 25, 2022

Sponsor

Lead sponsor
BenQ Materials CorporationNot on our public-company list
Sponsor type
Industry
First posted
Sep 27, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project is an open, parallel, randomly controlled, and non-inferiority clinical trial of MSENCI soft hydrophilic contact lenses with Oxypure color soft hydrophilic contact lenses used as the control product.

Conditions

  • Myopia

Interventions

  • BenQ Materials MSENCI soft hydrophilic contact lensesDevice

    Test lenses were to be worn for approximately 90 days.

  • Visco Oxypure Color soft hydrophilic contact lensesDevice

    Control lenses were to be worn for approximately 90 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. efficacy evaluation indexesTime frame: after wearing lenses for 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • BenQ Materials Corporation

    Taoyuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.